Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Xu J, Tao J, Wang J
doi: 10.1126/science.aac7516 146 ZongW-XRabinowitzJDWhiteE
Fei Y, Tsoi MF, Cheung BMY (2019) Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Key research findings include: Average 24.2% body weight reduction in Phase 2 at the highest dose cohort over 48 weeks Significant reductions in waist circumference, triglycerides, and fasting glucose Weekly subcutaneous injection (half-life approximately 6 days) Most common adverse events: nausea, vomiting, diarrhea (typical of GLP-1 class) Requires cold chain storage (28C refrigerated)
US$ 21.44
US$ 23.49
US$ 20.89
US$ 21.27
US$ 28.86
